Nurix Therapeutics reports Q2 EPS (81c), consensus (72c)
Reports Q2 revenue $9.04M, consensus $15.29M. "The second quarter of 2026 was a defining period for Nurix and the targeted protein degradation field," said Arthur Sands, president and chief executive officer of Nurix. "Our global collaboration with Roche, an industry leader, validates both the differentiated clinical profile of bexobrutideg in malignant hematology and its broader potential in immunology and inflammation. The co-development, co-commercialization structure of the agreement allows Nurix to pursue multiple opportunities in significant markets in both oncology and autoimmune disease with financial strength and global reach."
Reports Q2 revenue $9.04M, consensus $15.29M. "The second quarter of 2026 was a defining period for Nurix and the targeted protein degradation field," said Arthur Sands, president and chief executive officer of Nurix. "Our global collaboration with Roche, an industry leader, validates both the differentiated clinical profile of bexobrutideg in malignant hematology and its broader potential in immunology and inflammation.
The co-development, co-commercialization structure of the agreement allows Nurix to pursue multiple opportunities in significant markets in both oncology and autoimmune disease with financial strength and global reach."